We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Curis (CRIS) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Curis (CRIS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Curis is one of 842 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. CRIS is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for CRIS's full-year earnings has moved 38.24% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that CRIS has returned about 56.57% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 1.62% on average. This means that Curis is performing better than its sector in terms of year-to-date returns.
Looking more specifically, CRIS belongs to the Medical - Biomedical and Genetics industry, which includes 345 individual stocks and currently sits at #58 in the Zacks Industry Rank. On average, stocks in this group have gained 9.77% this year, meaning that CRIS is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track CRIS. The stock will be looking to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Curis (CRIS) Outperforming Other Medical Stocks This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Curis (CRIS - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Curis is one of 842 companies in the Medical group. The Medical group currently sits at #1 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. CRIS is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for CRIS's full-year earnings has moved 38.24% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Our latest available data shows that CRIS has returned about 56.57% since the start of the calendar year. Meanwhile, stocks in the Medical group have gained about 1.62% on average. This means that Curis is performing better than its sector in terms of year-to-date returns.
Looking more specifically, CRIS belongs to the Medical - Biomedical and Genetics industry, which includes 345 individual stocks and currently sits at #58 in the Zacks Industry Rank. On average, stocks in this group have gained 9.77% this year, meaning that CRIS is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track CRIS. The stock will be looking to continue its solid performance.